Ignite Creation Date:
2025-12-25 @ 12:20 AM
Ignite Modification Date:
2026-02-21 @ 9:53 PM
Study NCT ID:
NCT03326258
Status:
WITHDRAWN
Last Update Posted:
2018-07-18
First Post:
2017-10-30
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery
Sponsor:
National Cancer Institute (NCI)
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Advanced Malignant Solid Neoplasm | View |
| None | Estrogen Receptor Negative | View |
| None | GPNMB Positive | View |
| None | HER2/Neu Negative | View |
| None | Metastatic Malignant Solid Neoplasm | View |
| None | Metastatic Melanoma | View |
| None | Progesterone Receptor Negative | View |
| None | Stage III Breast Cancer AJCC v7 | View |
| None | Stage III Cutaneous Melanoma AJCC v7 | View |
| None | Stage III Uveal Melanoma AJCC v7 | View |
| None | Stage IIIA Cutaneous Melanoma AJCC v7 | View |
| None | Stage IIIB Cutaneous Melanoma AJCC v7 | View |
| None | Stage IIIC Cutaneous Melanoma AJCC v7 | View |
| None | Stage IV Breast Cancer AJCC v6 and v7 | View |
| None | Stage IV Cutaneous Melanoma AJCC v6 and v7 | View |
| None | Stage IV Uveal Melanoma AJCC v7 | View |
| None | Triple-Negative Breast Carcinoma | View |
| None | Unresectable Solid Neoplasm | View |
Keywords: